株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

胃癌:パイプライン分析

Gastric Cancer - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232773
出版日 ページ情報 英文 963 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
胃癌:パイプライン分析 Gastric Cancer - Pipeline Review, H2 2016
出版日: 2016年10月26日 ページ情報: 英文 963 Pages
概要

胃癌は、胃の内膜に発生する悪性腫瘍で、その兆候と症状には、倦怠感、腹痛、嘔吐、体重の減少、食後の膨満感、胸やけ、消化不良などがあります。胃癌を罹患する原因としては、喫煙、2悪性貧血、胃のポリープ、ピロリ菌への感染、胃癌を発症しやすい家系などが挙げられます。

当レポートでは、胃癌治療薬におけるパイプライン製品の概要や治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

胃癌の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

胃癌:企業で開発中の治療薬

胃癌:大学/機関で研究中の治療薬

胃癌:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

胃癌:企業で開発中の製品

胃癌:大学/機関で研究中の製品

胃癌の治療薬開発に従事している企業

胃癌:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

胃癌:最近のパイプライン動向

胃癌:休止中のプロジェクト

胃癌:開発が中止された製品

胃癌:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8584IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H2 2016, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 68, 68, 7, 65, 6 and 2 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 3, 7 and 1 molecules, respectively for Gastric Cancer.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Gastric Cancer Overview
  • Therapeutics Development
  • Gastric Cancer - Therapeutics under Development by Companies
  • Gastric Cancer - Therapeutics under Investigation by Universities/Institutes
  • Gastric Cancer - Pipeline Products Glance
  • Gastric Cancer - Products under Development by Companies
  • Gastric Cancer - Products under Investigation by Universities/Institutes
  • Gastric Cancer - Companies Involved in Therapeutics Development
  • Gastric Cancer - Therapeutics Assessment
  • Drug Profiles
  • Gastric Cancer - Dormant Projects
  • Gastric Cancer - Discontinued Products
  • Gastric Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Gastric Cancer, H2 2016
  • Number of Products under Development for Gastric Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Gastric Cancer - Pipeline by 3SBio Inc., H2 2016
  • Gastric Cancer - Pipeline by AB Science SA, H2 2016
  • Gastric Cancer - Pipeline by AbbVie Inc, H2 2016
  • Gastric Cancer - Pipeline by AbGenomics International, Inc., H2 2016
  • Gastric Cancer - Pipeline by ADC Therapeutics Sarl, H2 2016
  • Gastric Cancer - Pipeline by Advaxis, Inc., H2 2016
  • Gastric Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016
  • Gastric Cancer - Pipeline by Agenus, Inc., H2 2016
  • Gastric Cancer - Pipeline by Almac Discovery Limited, H2 2016
  • Gastric Cancer - Pipeline by Alteogen Inc., H2 2016
  • Gastric Cancer - Pipeline by Ambrx, Inc., H2 2016
  • Gastric Cancer - Pipeline by Amgen Inc., H2 2016
  • Gastric Cancer - Pipeline by arGEN-X BV, H2 2016
  • Gastric Cancer - Pipeline by Asana BioSciences, LLC, H2 2016
  • Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016
  • Gastric Cancer - Pipeline by Astellas Pharma Inc., H2 2016
  • Gastric Cancer - Pipeline by AstraZeneca Plc, H2 2016
  • Gastric Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2016
  • Gastric Cancer - Pipeline by Athenex, Inc., H2 2016
  • Gastric Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2016
  • Gastric Cancer - Pipeline by Basilea Pharmaceutica Ltd., H2 2016
  • Gastric Cancer - Pipeline by Bayer AG, H2 2016
  • Gastric Cancer - Pipeline by BeiGene, Ltd., H2 2016
  • Gastric Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016
  • Gastric Cancer - Pipeline by Bionovis SA, H2 2016
  • Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Gastric Cancer - Pipeline by Boston Biomedical, Inc., H2 2016
  • Gastric Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Gastric Cancer - Pipeline by Calithera Biosciences, Inc., H2 2016
  • Gastric Cancer - Pipeline by Cancer Prevention Pharmaceuticals, Inc., H2 2016
  • Gastric Cancer - Pipeline by Celgene Corporation, H2 2016
  • Gastric Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016
  • Gastric Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2016
  • Gastric Cancer - Pipeline by Celltrion, Inc., H2 2016
  • Gastric Cancer - Pipeline by Celon Pharma Sp. z o.o., H2 2016
  • Gastric Cancer - Pipeline by Cerulean Pharma, Inc., H2 2016
  • Gastric Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016
  • Gastric Cancer - Pipeline by Curaxys, S.L., H2 2016
  • Gastric Cancer - Pipeline by DAE HWA Pharmaceutical Co., Ltd., H2 2016
  • Gastric Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Gastric Cancer - Pipeline by Debiopharm International SA , H2 2016
  • Gastric Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016
  • Gastric Cancer - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016
  • Gastric Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
  • Gastric Cancer - Pipeline by Eddingpharm, H2 2016
  • Gastric Cancer - Pipeline by EirGenix Inc., H2 2016
  • Gastric Cancer - Pipeline by Eli Lilly and Company, H2 2016
  • Gastric Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2016
  • Gastric Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Gastric Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2016
  • Gastric Cancer - Pipeline by Frost Biologic, Inc., H2 2016
  • Gastric Cancer - Pipeline by Galena Biopharma, Inc., H2 2016
  • Gastric Cancer - Pipeline by Genelux Corporation, H2 2016
  • Gastric Cancer - Pipeline by Genentech, Inc., H2 2016
  • Gastric Cancer - Pipeline by Gilead Sciences, Inc., H2 2016
  • Gastric Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Gastric Cancer - Pipeline by GlycoNex Inc., H2 2016
  • Gastric Cancer - Pipeline by Glycotope GmbH, H2 2016
  • Gastric Cancer - Pipeline by Green Cross Corporation, H2 2016
  • Gastric Cancer - Pipeline by Halozyme Therapeutics, Inc., H2 2016
  • Gastric Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
  • Gastric Cancer - Pipeline by Horizon Pharma Plc, H2 2016
  • Gastric Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016
  • Gastric Cancer - Pipeline by Ignyta, Inc., H2 2016
  • Gastric Cancer - Pipeline by Immunomedics, Inc., H2 2016
  • Gastric Cancer - Pipeline by Imugene Limited, H2 2016
  • Gastric Cancer - Pipeline by Incyte Corporation, H2 2016
  • Gastric Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
  • Gastric Cancer - Pipeline by INSYS Therapeutics, Inc., H2 2016
  • Gastric Cancer - Pipeline by Intezyne Technologies, Inc., H2 2016
  • Gastric Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
  • Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2016
  • Gastric Cancer - Pipeline by Johnson & Johnson, H2 2016
  • Gastric Cancer - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2016
  • Gastric Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Gastric Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016
  • Gastric Cancer - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2016
  • Gastric Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016
  • Gastric Cancer - Pipeline by LegoChem Biosciences, Inc, H2 2016
  • Gastric Cancer - Pipeline by Les Laboratoires Servier SAS, H2 2016
  • Gastric Cancer - Pipeline by MacroGenics, Inc., H2 2016
  • Gastric Cancer - Pipeline by MaxiVAX SA, H2 2016
  • Gastric Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2016
  • Gastric Cancer - Pipeline by MedImmune, LLC, H2 2016
  • Gastric Cancer - Pipeline by Medivation, Inc., H2 2016
  • Gastric Cancer - Pipeline by Merck & Co., Inc., H2 2016
  • Gastric Cancer - Pipeline by Merck KGaA, H2 2016
  • Gastric Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
  • Gastric Cancer - Pipeline by Mersana Therapeutics, Inc., H2 2016
  • Gastric Cancer - Pipeline by Merus NV, H2 2016
  • Gastric Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Gastric Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2016
  • Gastric Cancer - Pipeline by Molecular Targeting Technologies, Inc., H2 2016
  • Gastric Cancer - Pipeline by MolMed S.p.A., H2 2016
  • Gastric Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2016
  • Gastric Cancer - Pipeline by NeuClone Pty Ltd, H2 2016
  • Gastric Cancer - Pipeline by Novartis AG, H2 2016
  • Gastric Cancer - Pipeline by OBI Pharma, Inc., H2 2016
  • Gastric Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2016
  • Gastric Cancer - Pipeline by Oncobiologics, Inc., H2 2016
  • Gastric Cancer - Pipeline by Oncolys BioPharma Inc, H2 2016
  • Gastric Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016
  • Gastric Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016
  • Gastric Cancer - Pipeline by OncoTherapy Science, Inc., H2 2016
  • Gastric Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Gastric Cancer - Pipeline by Opsona Therapeutics Limited, H2 2016
  • Gastric Cancer - Pipeline by Panacea Biotec Limited, H2 2016
  • Gastric Cancer - Pipeline by Patrys Limited, H2 2016
  • Gastric Cancer - Pipeline by Pfizer Inc., H2 2016
  • Gastric Cancer - Pipeline by Pharma Mar, S.A., H2 2016
  • Gastric Cancer - Pipeline by Puma Biotechnology, Inc., H2 2016
  • Gastric Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016
  • Gastric Cancer - Pipeline by Rgenix, Inc., H2 2016
  • Gastric Cancer - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016
  • Gastric Cancer - Pipeline by Richter Gedeon Nyrt., H2 2016
  • Gastric Cancer - Pipeline by Samumed LLC, H2 2016
  • Gastric Cancer - Pipeline by Sanofi, H2 2016
  • Gastric Cancer - Pipeline by Sequella, Inc., H2 2016
  • Gastric Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016
  • Gastric Cancer - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Gastric Cancer - Pipeline by Simcere Pharmaceutical Group, H2 2016
  • Gastric Cancer - Pipeline by Sorrento Therapeutics, Inc., H2 2016
  • Gastric Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
  • Gastric Cancer - Pipeline by Supratek Pharma Inc., H2 2016
  • Gastric Cancer - Pipeline by SynCore Biotechnology Co., Ltd., H2 2016
  • Gastric Cancer - Pipeline by Synovo GmbH, H2 2016
  • Gastric Cancer - Pipeline by Synthon Holdings BV, H2 2016
  • Gastric Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
  • Gastric Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
  • Gastric Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Gastric Cancer - Pipeline by Takis S.r.l., H2 2016
  • Gastric Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016
  • Gastric Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016
  • Gastric Cancer - Pipeline by Transgene SA, H2 2016
  • Gastric Cancer - Pipeline by United BioPharma, Inc., H2 2016
  • Gastric Cancer - Pipeline by Vaxon Biotech, H2 2016
  • Gastric Cancer - Pipeline by XuanZhu Pharma Co., Ltd., H2 2016
  • Gastric Cancer - Pipeline by Zymeworks Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Gastric Cancer - Dormant Projects, H2 2016
  • Gastric Cancer - Dormant Projects (Contd..1), H2 2016
  • Gastric Cancer - Dormant Projects (Contd..2), H2 2016
  • Gastric Cancer - Dormant Projects (Contd..3), H2 2016
  • Gastric Cancer - Dormant Projects (Contd..4), H2 2016
  • Gastric Cancer - Dormant Projects (Contd..5), H2 2016
  • Gastric Cancer - Dormant Projects (Contd..6), H2 2016
  • Gastric Cancer - Dormant Projects (Contd..7), H2 2016
  • Gastric Cancer - Dormant Projects (Contd..8), H2 2016
  • Gastric Cancer - Dormant Projects (Contd..9), H2 2016
  • Gastric Cancer - Dormant Projects (Contd..10), H2 2016
  • Gastric Cancer - Dormant Projects (Contd..11), H2 2016
  • Gastric Cancer - Dormant Projects (Contd..12), H2 2016
  • Gastric Cancer - Discontinued Products, H2 2016
  • Gastric Cancer - Discontinued Products (Contd..1), H2 2016
  • Gastric Cancer - Discontinued Products (Contd..2), H2 2016
  • Gastric Cancer - Discontinued Products (Contd..3), H2 2016

List of Figures

  • Number of Products under Development for Gastric Cancer, H2 2016
  • Number of Products under Development for Gastric Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top